Trial reportIrish journal of medical science2014
Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction.
Trial report in Irish journal of medical science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- A systematic review of non-surgical management in Peyronie's disease.International journal of impotence research · 2023Pooled it
- Non-surgical therapies for Peyronie's disease.The Cochrane database of systematic reviews · 2023Pooled it
- Contemporary Management Strategies for Peyronie's Disease: A Comprehensive Review.Research and reports in urology · 2026Review
- Outcomes and management of Peyronie's disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil.Asian journal of andrology · 2025Article
- Inhibition of phosphodiesterases 1 and 4 prevents myofibroblast transformation in Peyronie's disease.BJU international · 2025Article
- Acute Phase Peyronie's Disease: Where Do We Stand?Cureus · 2024Review
- Conservative treatment of Peyronie's disease: a guide.World journal of urology · 2024Review
- Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis.International journal of impotence research · 2024Article
- Commentary on "Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie's disease: a retrospective cohort study".International journal of impotence research · 2024Article
- Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie's Disease: A retrospective cohort study.International journal of impotence research · 2024Article
- [Current treatment concepts for Peyronie's disease].Urologie (Heidelberg, Germany) · 2023Article
- Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.Current urology reports · 2021Review
- Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.Frontiers in pharmacology · 2021Review
- Nonsurgical management of Peyronie's disease.Nature reviews. Urology · 2019Review
- Relationship between Response to PDE5 Inhibitors and Penile Duplex Doppler Ultrasound in Erectile Dysfunction.Medical sciences (Basel, Switzerland) · 2018Article
- Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction.Translational andrology and urology · 2017Review
- Nonsurgical treatment options in Peyronie's Disease: 2016 update.Turkish journal of urology · 2016Review
- Article
- Oral therapy for Peyronie's disease, does it work?Translational andrology and urology · 2016Review
- 2013-2014 updates in Peyronie's disease management.Current urology reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt has been shown on experimental rat models that type 5-phosphodiesterase isoenzyme (PDE5) inhibitors have anti-fibrotic effects for Peyronie's disease (PD); however, this issue has not been addressed clinically. The aim of this study was to document the effects of PDE5 inhibitors used for erectile dysfunction (ED) seen in PD patients on the main course of the PD clinically.
methodsA total of 39 PD patients with ED were divided into two groups. Patients in Group 1 (n = 18) served as controls and received 400 IU vitamin E per day. Those in Group 2 (n = 21) received 50 mg sildenafil per day for 12 weeks. Penile plaque volume was assessed by palpation and by duplex ultrasound. Erectile capacity, penile deformity and plaque characteristics were assessed by the International Index of Erectile Function questionnaire form (IIEF-5) and penile duplex ultrasound.
resultsStatistically significant improvement in all parameters was observed within both groups except for IIEF score in Group 1 when compared with the initial values. Significant reduction in plaques and pain were observed in 7 (33.3 %) and 14 (66.6 %) patients in Group 2 and 6 (33.3 %) and 9 patients (42.8 %) in Group 1, respectively. At the end of the therapy, improvement in IIEF score and reduction in pain were statistically significant in Group 2 compared with Group 1 (p = 0.028 and p = 0.045, respectively).
conclusionWe conclude that continuous administration of oral PDE5 inhibitors may be a candidate for medical treatment of PD; however, more controlled studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.